2451856-97-4
2451856-97-4 structure
- Name: Mupadolimab
- Chemical Name: Mupadolimab
- CAS Number: 2451856-97-4
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Infection
- Create Date: 2022-11-13 15:46:39
- Modify Date: 2024-01-04 16:55:00
-
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells[1].
| Name | Mupadolimab |
|---|
| Description | Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells[1]. |
|---|---|
| Related Catalog | |
| Target |
CD73[1] |
| In Vitro | Mupadolimab induces the increased expression of markers associated with B cell maturation and antigen presentation, morphologic transformation to plasmablasts, and increased secretion of IgM and IgG[1]. |
| In Vivo | Mupadolimab (10 mg/kg; i.p.; daily for 15 days) stimulates antigen specific humoral immunity in SARS-CoV-2 infected NSG-SGM3 mice[1]. Animal Model: NSG-SGM3 mice, immunized with an emulsion of 50 μg full length spike protein from SARS-CoV-2 and Freund’s Incomplete Adjuvant subcutaneously on both the left and right flank (25 μg/side)[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection, daily for 15 days Result: Mice treated with the drug made antibodies to the immunizing TS protein; but not to the control nucleocapsid SARS-CoV-2 viral protein. |
| References |
| No Any Chemical & Physical Properties |